Miph.Ca
MIPH.CA is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Business. MIPH.CA is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MIPH.CA is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
MIPH.CA maintains a debt-to-equity ratio of 1.27, indicating a moderate reliance on debt financing, and a current ratio of 1.25, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow is negative at -513.4 million, and capital expenditures are -919.1 million, signaling significant investment in long-term assets. The company's liquidity position is assessed as medium risk, with net cash being negative after subtracting total debt.
In terms of profitability, MIPH.CA reports a return on equity (ROE) of 3.65% and a return on assets (ROA) of 1.31%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, indicating that the company is generating relatively modest returns on its equity and asset base.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher operational and market risks.
Looking ahead, MIPH.CA is projected to experience a growth trajectory based on its current financial performance and capital expenditures. The company's operating cash flow of 221.5 million and net income of 157.1 million suggest a stable earnings base, but the negative free cash flow and high capital expenditures indicate that the company is reinvesting heavily in its operations. The outlook for the next fiscal year is not explicitly provided, but the current year's performance suggests a cautious approach to growth.
The risk assessment for MIPH.CA highlights a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet short-term obligations without additional financing. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.
Recent events and filings for MIPH.CA include the latest financial statements and disclosures related to its capital structure and operating performance. No specific recent events or transcripts are provided in the available data, but the company's financial snapshot indicates ongoing investment in long-term assets and a focus on maintaining liquidity.
- MIPH.CA has a moderate debt-to-equity ratio and a current ratio that suggests it can cover its short-term liabilities.
- The company's ROE and ROA are below typical industry benchmarks, indicating modest returns on equity and assets.
- MIPH.CA's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is investing heavily in long-term assets, as evidenced by its negative free cash flow and high capital expenditures.
- MIPH.CA faces medium liquidity risk and low dilution risk, with a negative net cash position after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MIPH.CA Market data — financials · 2026-05-28